Analyze Diet
Equine veterinary journal2026; doi: 10.1002/evj.70353

An equine bone marrow aspirate concentrate protocol yields a predictable cellular and cytokine profile.

Abstract: Bone marrow aspirate concentrate (BMAC) is a quick, minimally invasive, point-of-care therapy for equine orthopaedic injuries. Despite growing clinical use, standardised manufacturing methods are lacking, and the final product remains poorly characterised. Objective: To develop a reproducible protocol for equine BMAC production that yields predictable cellular and cytokine compositions. Methods: In vitro analytical study. Methods: Bone marrow aspirate (BMA) was harvested from the sternum of eight healthy adult horses and filtered to remove possible bony spicules. After centrifugation at 1000 × g for 10 min, the buffy coat was collected to generate BMAC. Cellular composition was assessed using standard haematology and cytology, and cytokine concentrations were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Data are presented as mean ± standard deviation. Results: BMA filtration successfully removed potential bony material without significantly altering the cellular profile. Cells were predictably concentrated in BMAC: total nucleated cells increased from 77 ± 30 × 10/μL to 240 ± 57 × 10/μL; and platelets from 119 ± 34 × 10/μL to 269 ± 81 × 10/μL. Anti-inflammatory cytokines were increased in BMAC: IL-1ra increased from 18,611.3 ± 5509.1 to 36,598.8 ± 5971.8 pg/mL; IL-10 from 9.0 ± 7.5 to 19.1 ± 15.6 ng/mL; and TGF-β1 from 2535.0 ± 3018.7 to 5073.8 ± 2175.9 pg/mL. Of the pro-inflammatory cytokines measured, only IL-1β was increased (287.5 ± 22.5 to 475.1 ± 206.0 pg/mL), while TNF-α and IL-6 were unchanged. Conclusions: The small cohort size (n = 8) limited sensitivity for detecting minor effects. The cytokine panel, while representative, does not encompass all potential bioactive mediators, and single-time-point measurements do not necessarily reflect in vivo release kinetics. The clinical efficacy of BMAC was not evaluated, preventing direct correlation between compositional features and therapeutic outcomes. Conclusions: The BMAC protocol yielded consistently concentrated nucleated cells, preserved cellular morphology, and enhanced the anti-inflammatory cytokine profile relative to post-filtration BMA. These findings provide a biological rationale for intra-articular and intra-lesional use of BMAC in equine patients.
Publication Date: 2026-11-15 PubMed ID: 43036173DOI: 10.1002/evj.70353Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This study developed and validated a reproducible protocol for producing equine bone marrow aspirate concentrate (BMAC) with consistent cellular and cytokine compositions.
  • The research showed that the protocol effectively concentrates nucleated cells and increases anti-inflammatory cytokines, supporting the potential therapeutic use of BMAC for horse orthopedic injuries.

Background and Objective

  • Bone marrow aspirate concentrate (BMAC) is increasingly used as a point-of-care treatment for equine orthopedic injuries because it is quick and minimally invasive.
  • Despite its growing use, there is no standardized, well-characterized method to prepare BMAC, limiting understanding of its composition and effectiveness.
  • The study aimed to establish a reproducible protocol to produce BMAC from equine bone marrow that yields predictable cellular and cytokine profiles, which are important for therapeutic efficacy.

Methods

  • Sample collection: Bone marrow aspirate (BMA) was obtained from the sternum of eight healthy adult horses.
  • Filtration process: The BMA was filtered to remove bony spicules, which are small bone fragments that could interfere with downstream processing.
  • Centrifugation: The filtered BMA was centrifuged at 1000 × g for 10 minutes to separate components; the buffy coat layer was collected to create the BMAC.
  • Analysis:
    • Cellular components were measured using standard hematology and cytology techniques to identify total nucleated cells and platelets.
    • Cytokine levels, which play roles in inflammation and healing, were quantified with enzyme-linked immunosorbent assay (ELISA) kits for both anti-inflammatory and pro-inflammatory cytokines.
    • Data were summarized as mean ± standard deviation.

Results

  • Filtration outcome: Successfully removed bony fragments without significantly changing the cellular profile of the aspirate.
  • Cellular concentration:
    • Total nucleated cells increased significantly from 77 ± 30 × 10/μL in filtered BMA to 240 ± 57 × 10/μL in BMAC.
    • Platelets increased from 119 ± 34 × 10/μL to 269 ± 81 × 10/μL.
  • Cytokine changes:
    • Anti-inflammatory cytokines showed marked increases:
      • IL-1 receptor antagonist (IL-1ra) rose from 18,611.3 ± 5509.1 to 36,598.8 ± 5971.8 pg/mL.
      • Interleukin-10 (IL-10) increased from 9.0 ± 7.5 to 19.1 ± 15.6 ng/mL.
      • Transforming growth factor-beta 1 (TGF-β1) increased from 2535.0 ± 3018.7 to 5073.8 ± 2175.9 pg/mL.
    • Among pro-inflammatory cytokines:
      • Interleukin-1 beta (IL-1β) increased from 287.5 ± 22.5 to 475.1 ± 206.0 pg/mL.
      • Tumor necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6) levels remained unchanged.

Limitations

  • The sample size was small (eight horses), limiting the ability to detect subtle effects and variability between individuals.
  • The cytokine panel tested was not exhaustive, so other relevant bioactive molecules might have been missed.
  • Measurements were taken at a single time point, which may not reflect the dynamics of cytokine release in living tissue over time.
  • The study did not assess the clinical efficacy or healing outcomes after BMAC treatment, so direct links between composition and therapeutic benefit remain unclear.

Conclusions and Implications

  • The developed protocol reproducibly concentrates nucleated cells and platelets without damaging cell morphology.
  • The process enhances anti-inflammatory cytokines, which could contribute to the healing environment in orthopedic injuries.
  • The increase in IL-1β, a pro-inflammatory cytokine, might play a complex role in tissue healing, though further study is needed.
  • This biological characterization supports the rationale for using BMAC intra-articularly (within joints) or intra-lesionally (within injury sites) in equine patients.
  • Future studies should include clinical trials to correlate these cellular and cytokine profiles with treatment outcomes in horses.

Cite This Article

APA
Branning M, Gordon J, Schlemmer SN, Peroni JF. (2026). An equine bone marrow aspirate concentrate protocol yields a predictable cellular and cytokine profile. Equine Vet J. https://doi.org/10.1002/evj.70353

Publication

ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English

Researcher Affiliations

Branning, Megan
  • Department of Large Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Gordon, Julie
  • Department of Large Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Schlemmer, Samantha N
  • Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Peroni, John F
  • Department of Large Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.

References

This article includes 44 references
  1. Costa FR, Pires L, Martins RA, Santos M, Santos GS, Lana JV. Orthobiologics revisited: a concise perspective on regenerative orthopedics. Curr Issues Mol Biol 2025;47:247.
    doi: 10.3390/cimb47040247google scholar: lookup
  2. Hauser RA, Orlofsky A. Regenerative injection therapy with whole bone marrow aspirate for degenerative joint disease: a case series. Clin Med Insights Arthritis Musculoskelet Disord 2013;6:65–72.
    doi: 10.4137/cmamd.s10951google scholar: lookup
  3. Long S, Maleas G, Belacic ZA, Quam VG, Durgam S. Equine bone marrow aspirate and bone marrow aspirate concentrate are enriched with interleukin‐1 receptor antagonist protein. Am J Vet Res 2025;86:86.
    doi: 10.2460/ajvr.24.12.0380google scholar: lookup
  4. Fortier LA, Potter HG, Rickey EJ, Schnabel LV, Foo LF, Chong LR. Concentrated bone marrow aspirate improves full‐thickness cartilage repair compared with microfracture in the equine model. J Bone Joint Surg Am 2010;92:1927–1937.
    doi: 10.2106/jbjs.i.01284google scholar: lookup
  5. Chu CR, Fortier LA, Williams A, Payne KA, McCarrel T, Bowers ME. Minimally manipulated bone marrow concentrate compared with microfracture treatment of full‐thickness chondral defects: a one‐year study in an equine model. J Bone Joint Surg Am 2018;100:138–146.
    doi: 10.2106/jbjs.17.00132google scholar: lookup
  6. Maleas G, Mageed M. Effectiveness of platelet‐rich plasma and bone marrow aspirate concentrate as treatments for chronic hindlimb proximal suspensory desmopathy. Front Vet Sci 2021;8:678453.
    doi: 10.3389/fvets.2021.678453google scholar: lookup
  7. Schafer R, DeBaun MR, Fleck E, Centeno CJ, Kraft D, Leibacher J. Quantitation of progenitor cell populations and growth factors after bone marrow aspirate concentration. J Transl Med 2019;17:115.
    doi: 10.1186/s12967-019-1866-7google scholar: lookup
  8. Sheehan DC, Hrapchak BB. Theory and practice of histotechnology. 2nd ed. Columbus, OH: Battelle Press; 1987.
  9. Bancroft JD, Gamble M. Theory and practice of histological techniques. 6th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2008.
  10. Walton RM, Cowell RL, Valenciano AC. Equine hematology, cytology, and clinical chemistry. 2nd ed. Hoboken, NJ: Wiley‐Blackwell; 2021.
  11. Fortier LA. Equine bone marrow aspirate concentrate. Vet Clin North Am Equine Pract 2023;39:453–459.
  12. Cassano JM, Kennedy JG, Ross KA, Fraser EJ, Goodale MB, Fortier LA. Bone marrow concentrate and platelet‐rich plasma differ in cell distribution and interleukin 1 receptor antagonist protein concentration. Knee Surg Sports Traumatol Arthrosc 2018;26:333–342.
    doi: 10.1007/s00167-016-3981-9google scholar: lookup
  13. Dragoo JL, Guzman RA. Evaluation of the consistency and composition of commercially available bone marrow aspirate concentrate systems. Orthop J Sports Med 2020;8:2325967119893634.
    doi: 10.1177/2325967119893634google scholar: lookup
  14. Hegde V, Shonuga O, Ellis S, Fragomen A, Kennedy J, Kudryashov V. A prospective comparison of 3 approved systems for autologous bone marrow concentration demonstrated nonequivalency in progenitor cell number and concentration. J Orthop Trauma 2014;28:591–598.
  15. Gaul F, Bugbee WD, Hoenecke HR Jr, D'Lima DD. A review of commercially available point‐of‐care devices to concentrate bone marrow for the treatment of osteoarthritis and focal cartilage lesions. Cartilage 2019;10:387–394.
    doi: 10.1177/1947603518768080google scholar: lookup
  16. Chandrashekar S, Jeyaraman M, Mounissamy P, Jeyaraman N, Khanna M, Gupta A. Safety and efficacy of bone‐marrow aspirate concentrate in hip osteoarthritis: a systematic review of current clinical evidence.. Indian J Orthop 2024;58:835–844.
  17. Kasashima Y, Ueno T, Tomita A, Goodship AE, Smith RKW. Optimisation of bone marrow aspiration from the equine sternum for the safe recovery of mesenchymal stem cells.. Equine Vet J 2011;43:288–294.
  18. Delling U, Lindner K, Ribitsch I, Jülke H, Brehm W. Comparison of bone marrow aspiration at the sternum and the tuber coxae in middle‐aged horses.. Can J Vet Res 2012;76:52–56.
  19. Cohn RM, Schwarzkopf R, Jaffe F. Heterotopic ossification after total hip arthroplasty.. Am J Orthop (Belle Mead NJ) 2011;40:E232–E235.
  20. Shields JS, Mofidi A, Ward WG, Jinnah RH. Does a plastic drape reduce incidence of heterotopic ossification after hip resurfacing?. Clin Orthop Relat Res 2011;469:1606–1613.
    doi: 10.1007/s11999-010-1606-zgoogle scholar: lookup
  21. Kantak AP, Shah NN. Extensive surgical wound lavage reduces the incidence and severity of heterotopic ossification in primary total hip replacement: a study of 175 hip replacements.. Hip Pelvis 2017;29:234–239.
    doi: 10.5371/hp.2017.29.4.234google scholar: lookup
  22. Camargo Garbin L, Lopez C, Carmona JU. A critical overview of the use of platelet‐rich plasma in equine medicine over the last decade.. Front Vet Sci 2021;8:641818.
    doi: 10.3389/fvets.2021.641818google scholar: lookup
  23. Hraha TH, Doremus KM, McIlwraith CW, Frisbie DD. Autologous conditioned serum: the comparative cytokine profiles of two commercial methods (IRAP and IRAP II) using equine blood.. Equine Vet J 2011;43:516–521.
  24. Fortier LA, Lintz M. Basic science of resident stem cells.. Oper Tech Sports Med 2020;28:150776.
  25. Commins J, Irwin R, Matuska A, Goodale M, Delco M, Fortier L. Biological mechanisms for cartilage repair using a BioCartilage scaffold: cellular adhesion/migration and bioactive proteins.. Cartilage 2021;13:984S–992S.
    doi: 10.1177/1947603519900803google scholar: lookup
  26. Belk JW, Lim JJ, Keeter C, McCulloch PC, Houck DA, McCarty EC. Patients with knee osteoarthritis who receive platelet‐rich plasma or bone marrow aspirate concentrate injections have better outcomes than patients who receive hyaluronic acid: systematic review and meta‐analysis.. Arthroscopy 2023;39:1714–1734.
  27. Han JH, Jung M, Chung K, Jung SH, Choi CH, Kim SH. Bone marrow aspirate concentrate injections for the treatment of knee osteoarthritis: a systematic review of randomized controlled trials.. Orthop J Sports Med 2024;12:23259671241296555.
    doi: 10.1177/23259671241296555google scholar: lookup
  28. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ. Synovial interleukin‐1 receptor antagonist and interleukin‐1 balance in rheumatoid arthritis.. Arthritis Rheum 1994;37:644–652.
    doi: 10.1002/art.1780370507google scholar: lookup
  29. O'Farrell AM, Liu Y, Moore KW, Mui ALF. IL‐10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3‐dependent and ‐independent pathways.. EMBO J 1998;17:1006–1018.
    doi: 10.1093/emboj/17.4.1006google scholar: lookup
  30. Deng ZQ, Fan T, Xiao C, Deng Z, Tian H, Zheng Y. TGF‐β signaling in health, disease, and therapeutics.. Signal Transduct Target Ther 2024;9:61.
  31. Imam MA, Holton J, Ernstbrunner L, Pepke W, Grubhofer F, Narvani A. A systematic review of the clinical applications and complications of bone marrow aspirate concentrate in management of bone defects and nonunions.. Int Orthop 2017;41:2213–2220.
    doi: 10.1007/s00264-017-3597-9google scholar: lookup
  32. Imam MA, Holton J, Horriat S, Negida AS, Grubhofer F, Gupta R. A systematic review of the concept and clinical applications of bone marrow aspirate concentrate in tendon pathology.. SICOT J 2017;3:58.
    doi: 10.1051/sicotj/2017039google scholar: lookup
  33. Lin YC, Chen YJ, Fan TY, Chou PH, Lu CC. Effect of bone marrow aspiration concentrate and platelet‐rich plasma combination in anterior cruciate ligament reconstruction: a randomized, prospective, double‐blinded study.. J Orthop Surg Res 2024;19:4.
  34. Muench LN, Kia C, Berthold DP, Uyeki C, Otto A, Cote MP. Preliminary clinical outcomes following biologic augmentation of arthroscopic rotator cuff repair using subacromial bursa, concentrated bone marrow aspirate, and platelet‐rich plasma.. Arthrosc Sports Med Rehabil 2020;2:e803–e813.
  35. Lee DH, Ryu KJ, Kim JW, Kang KC, Choi YR. Bone marrow aspirate concentrate and platelet‐rich plasma enhanced bone healing in distraction osteogenesis of the tibia.. Clin Orthop Relat Res 2014;472:3789–3797.
    doi: 10.1007/s11999-014-3548-3google scholar: lookup
  36. Gigante A, Cecconi S, Calcagno S, Busilacchi A, Enea D. Arthroscopic knee cartilage repair with covered microfracture and bone marrow concentrate.. Arthrosc Tech 2012;1:e175–e180.
  37. Gigante A, Calcagno S, Cecconi S, Ramazzotti D, Manzotti S, Enea D. Use of collagen scaffold and autologous bone marrow concentrate as a one‐step cartilage repair in the knee: histological results of second‐look biopsies at 1 year follow‐up.. Int J Immunopathol Pharmacol 2011;24:69–72.
  38. Geburek F, Gaus M, van Schie HT, Rohn K, Stadler PM. Effect of intralesional platelet‐rich plasma (PRP) treatment on clinical and ultrasonographic parameters in equine naturally occurring superficial digital flexor tendinopathies ‐ a randomized prospective controlled clinical trial.. BMC Vet Res 2016;12:191.
    doi: 10.1186/s12917-016-0826-1google scholar: lookup
  39. Garrett KS, Bramlage LR, Spike‐Pierce DL, Cohen ND. Injection of platelet‐ and leukocyte‐rich plasma at the junction of the proximal sesamoid bone and the suspensory ligament branch for treatment of yearling Thoroughbreds with proximal sesamoid bone inflammation and associated suspensory ligament branch desmitis.. J Am Vet Med Assoc 2013;243:120–125.
    doi: 10.2460/javma.243.1.120google scholar: lookup
  40. Wu WS, Chen LR, Chen KH. Platelet‐rich plasma (prp): molecular mechanisms, actions and clinical applications in human body.. Int J Mol Sci 2025;26:26.
    doi: 10.3390/ijms262110804google scholar: lookup
  41. Barot D, Usimaki A, Linardi RL, Arensberg CM, Ortved KF. Equine autologous blood‐based products contain variable quantities of transforming growth factor‐beta1, interleukin‐1 receptor antagonist, and alpha2‐macroglobulin.. Am J Vet Res 2025;86:ajvr.24.11.0363.
    doi: 10.2460/ajvr.24.11.0363google scholar: lookup
  42. Linardi RL, Dodson ME, Moss KL, King WJ, Ortved KF. The effect of autologous protein solution on the inflammatory cascade in stimulated equine chondrocytes.. Front Vet Sci 2019;6:64.
    doi: 10.3389/fvets.2019.00064google scholar: lookup
  43. Ziegler CG, Van Sloun R, Gonzalez S, Whitney KE, DePhillipo NN, Kennedy MI. Characterization of growth factors, cytokines, and chemokines in bone marrow concentrate and platelet‐rich plasma: a prospective analysis.. Am J Sports Med 2019;47:2174–2187.
    doi: 10.1177/0363546519832003google scholar: lookup
  44. Sugaya H, Yoshioka T, Kato T, Taniguchi Y, Kumagai H, Hyodo K. Comparative analysis of cellular and growth factor composition in bone marrow aspirate concentrate and platelet‐rich plasma.. Bone Marrow Res 2018;2018:1549826.
    doi: 10.1155/2018/1549826google scholar: lookup

Citations

This article has been cited 0 times.